Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx risk communication meeting

Executive Summary

FDA public meeting to seek input on the agency's risk communication mechanisms is slated for Dec. 7-8. Discussion topics include patient information sheets, health care professional sheets, talk papers, public health advisories, CDER's educational campaigns and website. The meeting will be held at the National Transportation Safety Board boardroom and conference center in Washington, D.C. (1"The Pink Sheet" Sept. 19, 2005, p. 18)...

You may also be interested in...



FDA Public Meeting On Rx Risk, Benefit Communication Slated For December

FDA will hold a public hearing on ways to better communicate information about drug risks and benefits, FDA Drug Safety Oversight Board Executive Director Susan Cummins said at the PDA/FDA Joint Regulatory Conference in Washington, D.C. on Sept. 13

IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine

The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.

Cipla Granted Approval For First US Proventil Rival

Shortly after wrapping up a Phase III trial for its proposed generic Advair Diskus product in the US, Cipla has won FDA approval for the first generic Proventil HFA product, as it continues to build up steam in the US respiratory market.

Topics

UsernamePublicRestriction

Register

PS046392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel